替吉奥（TIROX）与DCF方案治疗晚期胃癌的短期疗效及安全性比较
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
作者信息
Dong Lei, Li Jing, Lou Xiao-Ping, Miao Jin-Hong, Lu Pei, Chang Zhi-Wei, Han Zhao-Feng
机构信息
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
Department of Nursing, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
出版信息
J Int Med Res. 2014 Jun;42(3):737-43. doi: 10.1177/0300060513510657. Epub 2014 Apr 9.
OBJECTIVE
To compare the short-term efficacy and safety profile of the S-1 + irinotecan + oxaliplatin (TIROX) and docetaxel + cisplatin + flurouracil (DCF) anticancer regimens in patients with advanced gastric cancer.
METHODS
Patients with recurrent or metastatic gastric cancer diagnosed by pathology were randomly divided into two groups to receive six cycles of either the TIROX regimen (21-day cycle) or the DCF regimen (21-day cycle). After six chemotherapy cycles, the short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines and adverse reactions were recorded according to National Cancer Institute Common Toxicity Criteria 2.0 standards.
RESULTS
A total of 60 patients were enrolled in the study. The response rate (complete response + partial response) was significantly higher in the TIROX group (18/30 patients; 60.0%) compared with the DCF group (10/30 patients; 33.3%). The rates of grade III-IV leucopenia and neurotoxicity were significantly higher in the TIROX group than the DCF group.
CONCLUSION
The TIROX regimen was effective for the treatment of advanced gastric cancer, but it was associated with leucopenia and neurotoxicity.
目的
比较S-1+伊立替康+奥沙利铂（TIROX）与多西他赛+顺铂+氟尿嘧啶（DCF）抗癌方案治疗晚期胃癌患者的短期疗效和安全性。
方法
经病理诊断为复发性或转移性胃癌的患者被随机分为两组，接受六个周期的TIROX方案（21天周期）或DCF方案（21天周期）。六个化疗周期后，根据实体瘤疗效评价标准指南评估短期疗效，并根据美国国立癌症研究所通用毒性标准2.0标准记录不良反应。
结果
共有60例患者纳入研究。TIROX组的缓解率（完全缓解+部分缓解）显著高于DCF组（TIROX组18/30例患者，60.0%；DCF组10/30例患者，33.3%）。TIROX组III-IV级白细胞减少和神经毒性发生率显著高于DCF组。
结论
TIROX方案对晚期胃癌治疗有效，但与白细胞减少和神经毒性有关。
Zotero 插件